| Assessment Status | Rapid Review Complete |
| HTA ID | 23052 |
| Drug | Doxylamine/pyridoxine |
| Brand | Cariban® |
| Indication | Doxylamine/pyridoxine (Cariban®) is indicated for the symptomatic treatment of nausea and vomiting during pregnancy in adults who do not respond to conservative management. |
| Assessment Process | |
| Rapid review commissioned | 11/08/2023 |
| Rapid review completed | 30/08/2023 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that doxylamine/pyridoxine (Cariban®) not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement. March 2024.
